Supporting Publications

Azenosertib (WEE1 Inhibitor)

Correlation of Cyclin E1 Expression and Clinical Outcomes in a Phase 1b Dose-Escalation Study of Azenosertib (ZN-c3), a WEE1 inhibitor, in Combination with Chemotherapy (CT) in Patients (pts) with Platinum-Resistant or Refractory (R/R) Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer (EOC)

Liu, et al. (2023) American Society of Clinical Oncology

Cyclin E1 protein overexpression sensitizes ovarian cancer cells to azenosertib (ZN-c3), a novel, selective and orally bioavailable inhibitor of Wee1

Ma, J. et al. (2023) American Association for Cancer Research

Tumor Pharmacokinetics, Pharmacodynamics and Efficacy Analysis of WEE1 inhibitor, Azenosertib in Patient- Derived Xenograft Models of Glioblastoma

Patel, S. et al. (2023) American Association for Cancer Research

Preliminary data from a Phase 1 dose escalation study of ZN-c3 plus gemcitabine in relapsed/refractory osteosarcoma

Avutu, V. et al. (2022) Connective Tissue Oncology Society

A Phase 1/2 dose escalation and dose expansion study of ZN-c3 in combination with gemcitabine in adult and pediatric subjects with relapsed or refractory osteosarcoma

Avutu, V. et al. (2022) American Society for Clinical Oncology

ZN-c3, a potent and selective Wee1 inhibitor demonstrates anti-tumor activities in combination with other targeted therapies and overcomes PARP inhibitor resistance

Li, J. et al. (2022) American Association for Cancer Research

Safety and clinical activity of single-agent ZN-c3, an oral Wee1 inhibitor, in a Phase 1 trial in subjects with recurrent or advanced uterine serous carcinoma (USC)

Meric-Bernstam et al. (2022) American Association for Cancer Research

BH3 mimetics synergize with the Wee1 inhibitor ZN-c3 by activating caspases which induce DNA damage and degrade key proteins

Izadi, H. et al. (2022) American Association for Cancer Research

A Phase 1b dose-escalation study of ZN-c3, a Wee1 inhibitor, in combination with chemotherapy (CT) in subjects with platinum-resistant or refractory ovarian, peritoneal or fallopian tube cancer

Pasic, A. et al. (2022) American Association for Cancer Research

Phase 1b dose-escalation study of ZN-c3, a Wee1 inhibitor, in combination with chemotherapy in patients with platinum-resistant or -refractory ovarian, peritoneal, or fallopian tube cancer

Fu, S. et al. (2021) European Society for Medical Oncology

Pharmacodynamic evidence for Wee1 target engagement in surrogate and tumor tissues from a Phase 1 study of the Wee1 inhibitor ZN-c3

Chalasani, P. et al. (2021) European Society for Medical Oncology

Discovery of ZN-c3, a highly potent and selective Wee1 inhibitor undergoing evaluation in clinical trials for the treatment of cancer

Huang, P. et al. (2021) J. Med. Chem.

Discovery of ZN-c3, a potent Wee1 inhibitor with a differentiated pharmacologic and kinase selectivity profile

Li, J. et al. (2021) American Association for Cancer Research

ZN-d5 (BCL-2 Inhibitor)

A Phase 1/2 Dose Escalation Study of the BCL-2 Inhibitor ZN-d5 and the WEE1 Inhibitor Azenosertib (ZN-c3) in Patients (Pts) With Acute Myeloid Leukemia (AML)

Smith, et al. (2023) American Society of Clinical Oncology

A Phase 1/2 multi-center dose finding study to assess PK and efficacy of ZN-d5, a novel BCL-2 inhibitor for treatment of subjects with relapsed/refractory AL amyloidosis

Kastritis, E. et al. (2022) American Society of Hematology

Combination of the BCL-2 inhibitor ZN-d5 with the WEE1 inhibitor ZN-c3 shows additive or synergistic anti-tumor activity in acute myeloid leukemia (AML) models

Izadi, H. et al. (2022) American Association for Cancer Research

A Phase 1 dose-escalation study of ZN-d5, a BCL-2 inhibitor with improved selectivity, in subjects with advanced non-Hodgkin lymphoma (NHL) or acute myeloid leukemia (AML)

Zaucha, J. et al. (2021) European Society for Medical Oncology

Discovery of ZN-d5, a potent BCL-2 inhibitor with improved selectivity for BCL-2

Pinchman, J. et al. (2021) European Society for Medical Oncology